Comparative Pharmacology
Head-to-head clinical analysis: LOMANATE versus LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LOMANATE versus LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE.
LOMANATE vs LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
LOMANATE is a combination of diphenoxylate (a peripheral opioid receptor agonist that slows GI motility) and atropine (an anticholinergic that discourages abuse).
Loperamide binds to mu-opioid receptors in the intestinal wall, reducing peristalsis and increasing intestinal transit time, allowing for greater absorption of water and electrolytes. It also decreases fecal volume and increases stool consistency. Simethicone reduces the surface tension of gas bubbles in the stomach and intestines, facilitating their coalescence and passage via belching or flatulence.
100 mg orally twice daily
2 tablets (4 mg loperamide hydrochloride / 250 mg simethicone) orally after first loose stool, then 1 tablet (2 mg/125 mg) after each subsequent loose stool; maximum 4 tablets (8 mg/500 mg) per day for no more than 2 days.
None Documented
None Documented
Terminal elimination half-life is 18-24 hours in adults with normal renal function; prolonged to 40-60 hours in severe renal impairment (CrCl < 30 mL/min), requiring dose adjustment.
Loperamide: 7-14 hours (mean 10.8 hours) in healthy adults; prolonged to 18-26 hours in hepatic impairment.
Primarily renal (80% as unchanged drug and metabolites); biliary/fecal (15%); 5% eliminated via other routes.
Loperamide: 97% fecal, 3% renal. Simethicone: excreted unchanged in feces.
Category C
Category A/B
Antidiarrheal
Antidiarrheal